Knowledge base

Dutch medical innovations are rarely granted the Breakthrough Designation by the FDA. Startup ATRO Medical from Nijmegen is the new kid on the block in orthopedics. This week their Trammpolin® meniscus prosthesis (nowadays known as Artimis®), designed to treat chronic knee pain, received the Breakthrough Device Designation from the FDA. The designation demonstrates the innovation potential of this implant and expedites US market access by receiving a priority treatment at the FDA.

Orthopedic startup ATRO Medical enters a partnership together with the Dutch Arthritis Society for further development of the artificial meniscus. The Dutch startup works on a meniscus prosthesis for people with knee arthritis. The Dutch Arthritis Society supports these developments and shares its experience as patient expert in the field of arthritis. 

Introduction to ATRO Medical

An international consortium led by the Dutch med-tech startup ATRO Medical receives over € 800,000 EUROSTARS funding to address an unmet need for Knee Osteoarthritis patients. These patients often suffer from cartilage degradation related to a dysfunctional meniscus. Based on previous research, the consortium will develop a durable meniscus prosthesis for the outer knee compartment to relief pain and restore mobility. This would change the life of thousands of osteoarthritis patients.

Yess!! ATRO Medical has been named an Awardee in the Veterans Lead QuickFire Challenge organized by Johnson & Johnson Innovation!

The European Commission grants € 2.5 million to ATRO Medical for the accelerated development of their artificial meniscus. The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation.